Nonobstructive Hypertrophic Cardiomyopathy: Bisoprolol vs Verapamil 03/05/26
Welcome to Cardiology Today â Recorded March 05, 2026. This episode summarizes 5 key cardiology studies on topics like Computed tomography angiography and Verapamil. Key takeaway: Nonobstructive Hypertrophic Cardiomyopathy: Bisoprolol vs Verapamil.
Article Links:
Article 1: Finerenone in Type 1 Diabetes and Chronic Kidney Disease. (The New England journal of medicine)
Article 2: Coronary Atherosclerosis in Liver Transplant Recipients and Population Controls: A Nationwide Study Using Protocolized CT Angiography. (Journal of the American College of Cardiology)
Article 3: Intravascular Imaging- vs Angiography-Guided Complex PCI: 5-Year Outcomes From a Randomized Trial. (Journal of the American College of Cardiology)
Article 4: Beta-Blocker (Bisoprolol) vs Calcium-Channel Blocker (Verapamil) in Nonobstructive Hypertrophic Cardiomyopathy: A Randomized Triple-Crossover Physiologic Trial. (Journal of the American College of Cardiology)
Article 5: Heart Failure Quality of Care Among Asian Patients in the United States. (Journal of the American College of Cardiology)
Full episode page: https://podcast.explainheart.com/podcast/nonobstructive-hypertrophic-cardiomyopathy-bisoprolol-vs-verapamil-03-05-26/
đ Featured Articles
Article 1: Finerenone in Type 1 Diabetes and Chronic Kidney Disease.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41780000
Summary: Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, has demonstrated improvements in kidney and cardiovascular outcomes in patients with type two diabetes and chronic kidney disease. This established benefit prompted a phase three trial evaluating finerenone’s efficacy and safety in adults with type one diabetes and chronic kidney disease. The study included patients with an estimated glomerular filtration rate between 25 and less than 90 milliliters per minute per 1.73 meters squared, who also presented with albuminuria. This research directly addresses the potential therapeutic application of finerenone for improving outcomes in a distinct diabetic population.
Article 2: Coronary Atherosclerosis in Liver Transplant Recipients and Population Controls: A Nationwide Study Using Protocolized CT Angiography.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41778959
Summary: This nationwide cross-sectional study definitively characterized the prevalence and severity of coronary atherosclerosis in liver transplant recipients compared to control subjects. Researchers utilized protocolized research-coronary computed tomography angiography in both groups to overcome previous limitations of clinically indicated imaging or retrospective studies. This standardized approach provided a more robust assessment of coronary atherosclerotic burden. The study established a comprehensive profile of atherosclerotic disease in liver transplant patients.
Article 3: Intravascular Imaging- vs Angiography-Guided Complex PCI: 5-Year Outcomes From a Randomized Trial.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41778943
Summary: This randomized trial provided crucial long-term clinical outcomes comparing intravascular imaging-guided percutaneous coronary intervention with angiography-guided percutaneous coronary intervention for complex coronary artery lesions. The study definitively evaluated two distinct approaches for revascularization, assigning eligible patients in a two to one ratio to receive either imaging guidance or angiography guidance. This robust comparison established a clearer understanding of the relative long-term efficacy of each technique. The findings inform optimal strategies for percutaneous coronary intervention in challenging cases.
Article 4: Beta-Blocker (Bisoprolol) vs Calcium-Channel Blocker (Verapamil) in Nonobstructive Hypertrophic Cardiomyopathy: A Randomized Triple-Crossover Physiologic Trial.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41778690
Summary: This randomized, double-blinded, placebo-controlled triple-crossover trial directly compared the effects of bisoprolol and verapamil in patients with nonobstructive hypertrophic cardiomyopathy. The study rigorously evaluated the therapeutic impact of these two distinct drug classes, beta-blockers and calcium channel blockers. Patients included presented with at least one marker of disease severity, such as New York Heart Association functional class two or greater or N-terminal pro-B-type natriuretic peptide levels exceeding 300 nanograms per liter. This trial provided critical evidence regarding optimal pharmacologic management for this specific hypertrophic cardiomyopathy phenotype.
Article 5: Heart Failure Quality of Care Among Asian Patients in the United States.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41532945
Summary: This study identified crucial differences in the quality of inpatient heart failure care among individual groups of Asian patients compared with non-Hispanic White patients in the United States. Utilizing data from 824 U.S. hospitals within the Get With The Guidelines-Heart Failure registry from 2015 to 2023, the study rigorously assessed the odds of receiving optimal medical therapy. Optimal medical therapy was specifically defined as appropriate prescription of an angiotensin-converting enzyme inhibitor or angiotensin two receptor blocker, alongside a beta-blocker and a mineralocorticoid receptor antagonist. This research provided a detailed understanding of care disparities impacting diverse Asian heart failure populations.
đ Transcript
Today’s date is March 05, 2026. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. Finerenone in Type 1 Diabetes and Chronic Kidney Disease. Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, has demonstrated improvements in kidney and cardiovascular outcomes in patients with type two diabetes and chronic kidney disease. This established benefit prompted a phase three trial evaluating finerenone’s efficacy and safety in adults with type one diabetes and chronic kidney disease. The study included patients with an estimated glomerular filtration rate between 25 and less than 90 milliliters per minute per 1.73 meters squared, who also presented with albuminuria. This research directly addresses the potential therapeutic application of finerenone for improving outcomes in a distinct diabetic population.
Article number two. Coronary Atherosclerosis in Liver Transplant Recipients and Population Controls: A Nationwide Study Using Protocolized CT Angiography. This nationwide cross-sectional study definitively characterized the prevalence and severity of coronary atherosclerosis in liver transplant recipients compared to control subjects. Researchers utilized protocolized research-coronary computed tomography angiography in both groups to overcome previous limitations of clinically indicated imaging or retrospective studies. This standardized approach provided a more robust assessment of coronary atherosclerotic burden. The study established a comprehensive profile of atherosclerotic disease in liver transplant patients.
Article number three. Intravascular Imaging- vs Angiography-Guided Complex PCI: 5-Year Outcomes From a Randomized Trial. This randomized trial provided crucial long-term clinical outcomes comparing intravascular imaging-guided percutaneous coronary intervention with angiography-guided percutaneous coronary intervention for complex coronary artery lesions. The study definitively evaluated two distinct approaches for revascularization, assigning eligible patients in a two to one ratio to receive either imaging guidance or angiography guidance. This robust comparison established a clearer understanding of the relative long-term efficacy of each technique. The findings inform optimal strategies for percutaneous coronary intervention in challenging cases.
Article number four. Beta-Blocker (Bisoprolol) vs Calcium-Channel Blocker (Verapamil) in Nonobstructive Hypertrophic Cardiomyopathy: A Randomized Triple-Crossover Physiologic Trial. This randomized, double-blinded, placebo-controlled triple-crossover trial directly compared the effects of bisoprolol and verapamil in patients with nonobstructive hypertrophic cardiomyopathy. The study rigorously evaluated the therapeutic impact of these two distinct drug classes, beta-blockers and calcium channel blockers. Patients included presented with at least one marker of disease severity, such as New York Heart Association functional class two or greater or N-terminal pro-B-type natriuretic peptide levels exceeding 300 nanograms per liter. This trial provided critical evidence regarding optimal pharmacologic management for this specific hypertrophic cardiomyopathy phenotype.
Article number five. Heart Failure Quality of Care Among Asian Patients in the United States. This study identified crucial differences in the quality of inpatient heart failure care among individual groups of Asian patients compared with non-Hispanic White patients in the United States. Utilizing data from 824 U.S. hospitals within the Get With The Guidelines-Heart Failure registry from 2015 to 2023, the study rigorously assessed the odds of receiving optimal medical therapy. Optimal medical therapy was specifically defined as appropriate prescription of an angiotensin-converting enzyme inhibitor or angiotensin two receptor blocker, alongside a beta-blocker and a mineralocorticoid receptor antagonist. This research provided a detailed understanding of care disparities impacting diverse Asian heart failure populations.
Thank you for listening. Don’t forget to subscribe.
đ Keywords
Computed tomography angiography, Verapamil, Chronic kidney disease, Albuminuria, Mineralocorticoid receptor antagonist, Percutaneous coronary intervention, Intravascular imaging, Heart failure, Angiography-guided percutaneous coronary intervention, Control subjects, Bisoprolol, Liver transplant, Coronary atherosclerosis, Beta-blocker, Triple-crossover trial, Long-term outcomes, Complex coronary lesions, Finerenone, Optimal medical therapy, Nationwide study, Nonobstructive hypertrophic cardiomyopathy, Type one diabetes, Get With The Guidelines, Quality of care, Calcium channel blocker, Asian patients.
âšī¸ About
Concise summaries of cardiovascular research for professionals.
Subscribe âĸ Share âĸ Follow